Table 2.
Anti-nuclear antibodies (ANA) in different ANA associated autoimmune rheumatic diseases and healthy individuals.
| Antibody | AARD | |||||
|---|---|---|---|---|---|---|
| SLE | SSc | SjS | IIM | MCTD | HI | |
| dsDNA | 40–70% | <3% | <3% | <3% | <3% | <3% |
| Chromatin | 40–70% | <3% | <3% | <3% | 5–18% | <3% |
| RNP | 10–40% | 5–15% | <3% | 5–15% | 100%5 | <3% |
| Sm | 5–20% | <2% | <1% | <1% | <2%2 | <1% |
| SS-A/Ro60 | 40–70% | 3–10% | 60–90% | <3% | <3% | <3% |
| Ro52/ TRIM21 |
40–70% | 15–30% | 70–90% | 25–50% | <3% | <3% |
| SS-B/La | 15–30% | 1–5% | 60–80% | 5–15% | <3% | <3% |
| Scl-70 (topo I) | 0–5% | 20–40%4 | <3% | <3% | <3% | <1% |
| Jo-1 | 1–3% | 1–3% | <2% | 15–30% | <2% | <1% |
| Centromere | 2–5% | 20–40%4 | 5–10% | 1–3% | 2–5% | <3% |
| RNA Pol III | <1% | 5–25%4 | <1% | <1% | <1% | <1% |
| Ribosomal P | 10–30% | <2% | <2% | <2% | <2% | <1% |
| PM/Scl | 1–3% | 5–10% | <2% | 5–10% | <2% | <3% |
| Mi-2 | <1% | 3–8% | <1% | 5–15%1 | <1% | <3% |
| Ku | 5–20% | 3–8% | <3% | 3–10%3 | <3% | <3% |
| PCNA | <5% | <1% | <1% | <1% | <1% | <3% |
| Th/To | <1% | 3–10% | <1% | <1% | <1% | <1% |
1Rare in PM, higher prevalence in DM; mild form of disease; early during development.
2Prevalence depends if antigen contains SmBB′ (cross-reactive with RNP).
3Very high titer in PM.
4Anti-Scl-70, anti-centromere, anti-RNA Pol III antibodies tend to be mutually exclusive.
5Part of the classification criteria, therefore should be 100%; however, depending on assay used, some patients might be negative.
Note: Prevalence values were established based on literature and consensus of authors.
Abbreviations: DM: dermatomyositis; IIM: idiopathic inflammatory myopathy (polymyositis/dermatomyositis); MCTD: mixed connective tissue disease; PCNA: proliferating cell nuclear antigen; PM: polymyositis; RA: rheumatoid arthritis; RNA pol III: RNA polymerase III; RNP: ribonucleoprotein; Sm: Smith antigens (U2-U6 RNP); SjS: Sjögren's syndrome; SLE: systemic lupus erythematosus; SPA: Solid phase assay; SSc: systemic sclerosis; TRIM: tripartite motif.